The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 May 2026•

1 min read

Axsome Therapeutics Revenue Surges 57.4% as Auvelity Gains New FDA Approval

Key Facts

1Axsome Therapeutics achieved a 57.4% year-over-year revenue surge to $191.2 million in Q1 2026.

2The FDA approved Auvelity for the treatment of agitation in Alzheimer's patients.

3The company's COO sold 233 shares at $228.18 each as the stock approached its 52-week high.

Axsome Therapeutics reported robust financial results for the first quarter of 2026, with revenue surging 57.4% year-over-year to reach $191.2 million. This significant growth was primarily driven by a 59% increase in sales of its flagship drug, Auvelity, which recently secured FDA approval for treating agitation associated with Alzheimer's disease. Amidst this positive momentum, the company's stock approached its 52-week high of $234.29, prompting the COO to sell 233 shares at a price of $228.18. While the company faces a widening net loss, the regulatory milestone for Auvelity marks a critical expansion of its market potential in the biotechnology sector. Investors remain focused on the company's ability to scale its commercial operations following these latest clinical and regulatory successes. The combination of strong top-line growth and portfolio expansion underscores Axsome's current upward trajectory.